Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amenamevir - Maruho

X
Drug Profile

Amenamevir - Maruho

Alternative Names: Amenalief; ASP-2151; M-5220; M5220B

Latest Information Update: 22 Dec 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Maruho
  • Class Amides; Antivirals; Oxadiazoles; Small molecules
  • Mechanism of Action DNA helicase-primase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Herpes zoster
  • Phase III Herpes labialis; Herpes simplex virus infections

Most Recent Events

  • 03 Apr 2021 Maruho completes a phase III trial in Herpes labialis in Japan (JapicCTI-194954)
  • 01 Dec 2018 Maruho plans a phase I trial (Haemodialysis patients) in Japan (JapicCTI184242)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections(In volunteers) in United Kingdom (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top